Quest Diagnostics Incorporated (DGX): Price and Financial Metrics


Quest Diagnostics Incorporated (DGX)

Today's Latest Price: $125.06 USD

0.93 (-0.74%)

Updated Jan 27 3:38pm

Add DGX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 64 in Medical - Diagnostics/Research

See all "A" rated Strong Buy stocks

DGX Stock Summary

  • Quest Diagnostics Inc's market capitalization of $16,979,166,324 is ahead of 87.96% of US-listed equities.
  • Of note is the ratio of Quest Diagnostics Inc's sales and general administrative expense to its total operating expenses; 84.13% of US stocks have a lower such ratio.
  • The volatility of Quest Diagnostics Inc's share price is greater than that of merely 2.91% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to DGX, based on their financial statements, market capitalization, and price volatility, are IEX, BWA, ACGL, HEI, and AMCR.
  • Visit DGX's SEC page to see the company's official filings. To visit the company's web site, go to www.questdiagnostics.com.

DGX Stock Price Chart Interactive Chart >

Price chart for DGX

DGX Price/Volume Stats

Current price $125.06 52-week high $131.81
Prev. close $125.99 52-week low $73.02
Day low $124.50 Volume 1,200,165
Day high $127.38 Avg. volume 1,403,449
50-day MA $123.30 Dividend yield 1.78%
200-day MA $117.55 Market Cap 16.85B

Quest Diagnostics Incorporated (DGX) Company Bio


Quest Diagnostics provides diagnostic testing information services in the United States and internationally. The company offers clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services, and drugs-of-abuse testing, as well as related services and insights; laboratory testing services for new drugs, vaccines, and medical devices, analytic, on-site prevention, and wellness services, and risk assessment services for the life insurance industry. The company was founded in 1967 and is founded in Madison, New Jersey.

DGX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$125.06$206.53 64%

Below please find a table outlining a discounted cash flow forecast for DGX, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Quest Diagnostics Inc ranked in the 63th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 64.83% on a DCF basis. The most interesting components of our discounted cash flow analysis for Quest Diagnostics Inc ended up being:

  • The company has produced more trailing twelve month cash flow than 82.16% of its sector Healthcare.
  • Quest Diagnostics Inc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 12.06% of tickers in our DCF set.
  • DGX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than merely 12.06% of tickers in our DCF set.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%61%
1%62%
2%64%
3%66%
4%67%
5%69%

ANTM, MCK, DVA, CAH, and ANIP can be thought of as valuation peers to DGX, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


DGX Latest News Stream


Event/Time News Detail
Loading, please wait...

DGX Latest Social Stream


Loading social stream, please wait...

View Full DGX Social Stream

Latest DGX News From Around the Web

Below are the latest news stories about Quest Diagnostics Inc that investors may wish to consider to help them evaluate DGX as an investment opportunity.

As COVID-19 testing rolls on, Baird again boosting laboratory models

In healthcare, Baird still believes that labs are still not getting the respect they deserve. It's responding by raising its 2020 and 2021 models again, incorporating a sequential rise in COVID-19 testing that has the companies ready to "crush" quarterly expectations again. "Some investors remain apathetic about this catalyst," Eric...

Seeking Alpha | January 26, 2021

The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics

The Zacks Analyst Blog Highlights: ResMed, Invacare, Fresenius, Henry Schein and Quest Diagnostics

Yahoo | January 22, 2021

Pitt faculty, staff to have access to mail-in COVID-19 tests beginning Monday

Pitt faculty and staff received an email from the University’s COVID-19 Medical Response Office on Thursday afternoon outlining a new COVID-19 testing program through Quest Diagnostics as well as a vaccine and daily health check app update.After interest in surveillance COVID-19 testing of faculty and staff, the University has partnered with Quest Diagnostics to provide… The post Pitt faculty, staff to have access to mail-in COVID-19 tests beginning Monday appeared first on The Pitt News .

The Pitt News | January 21, 2021

Quest Diagnostics granted CDC contract to sequence COVID-19 gene variants

Quest Diagnostics (DGX) has entered into an agreement with the Centers for Disease Control and Prevention ((CDC)) to provide genomic sequencing to identify new mutations in, and patterns of transmission of SARS-CoV-2, the virus that causes COVID-19.Financial terms of the agreement are not disclosed. The company will perform the sequencing from its...

Seeking Alpha | January 18, 2021

Quest Diagnostics Wins Covid-19 Contract With US Health Agency

Quest Diagnostics has inked an agreement with the US Centers for Disease Control and Prevention (CDC) to provide genomic sequencing to identify new mutations and patterns of transmission of SARS-CoV-2, the virus that causes COVID-19. Quest (DGX) didn’t disclose the financial terms of the collaboration. As part of the agreement, the diagnostics company will help CDC in conducting a large-scale longitudinal genomic survey of the SARS-CoV-2 virus using a random set of samples collected from its labs across the US. Quest will conduct the sequencing from its advanced diagnostics laboratory in San Juan Capistrano, California.

Sharon Wrobel on TipRanks | January 18, 2021

Read More 'DGX' Stories Here

DGX Price Returns

1-mo 6.01%
3-mo 2.16%
6-mo -0.65%
1-year 15.34%
3-year 24.98%
5-year 110.79%
YTD 5.42%
2020 14.11%
2019 31.13%
2018 -13.84%
2017 9.16%
2016 31.90%

DGX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full DGX Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9955 seconds.